The effect of short-term dipyrone administration on cyclosporin pharmacokinetics

被引:15
作者
Caraco, Y [1 ]
Zylber-Katz, E
Fridlander, M
Admon, D
Levy, M
机构
[1] Hadassah Univ Hosp, Div Med, Clin Pharmacol Unit, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Nephrol, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Dept Cardiol, IL-91120 Jerusalem, Israel
关键词
cyclosporin; dipyrone; pharmacokinetics;
D O I
10.1007/s002280050659
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: A large number of drugs have been shown to affect the metabolism of cyclosporin A (CSA) and, since cyclosporin is characterized by a narrow therapeutic range, the consequences of such drug interactions may often be of clinical importance. Objective: To evaluate the effect of short-term administration of dipyrone on steady state CSA pharmacokinetics. Methods: Six kidney- and two heart-transplanted patients on chronic CSA therapy participated in this study, which consisted of two 4-day study periods separated by 3-week washout periods. The patients received, in addition to their usual drugs, dipyrone 500 mg or placebo t.i.d., as identical-looking tablets, and the order of administration was randomized. CSA concentrations were measured in whole blood by means of radio-immunoassay (CYCLO-Trac SP) daily during the study periods and periodically over 24 h on the fourth study day. Results: CSA concentrations over time were reduced after dipyrone (ANOVA, P < 0.01), but statistical significance was noted only at 2, 4, 5 and 10 h after drug intake (P < 0.05). Peak CSA concentration was not altered by dipyrone, but the time required to reach maximal concentration was longer with dipyrone treatment than with the placebo (3.8 +/- 2.6 h vs 2.1 +/- 0.6 h, P < 0.05). No consistent changes were noted for CSA trough level, elimination half-life and area under the concentration-time curve from 0 h to 12 h. Separate analysis of the kidney transplanted patients yielded similar results. Conclusions: Short-term administration of dipyrone is associated with a mild decrease in CSA blood concentration, which is most prominent in the first few hours after drug intake. In practice, no dose adjustment of CSA seems to be indicated during a short course of dipyrone treatment.
引用
收藏
页码:475 / 478
页数:4
相关论文
共 14 条
[1]   LONG-TERM EFFICACY AND SAFETY OF CYCLOSPORINE IN RENAL-TRANSPLANT RECIPIENTS [J].
BURKE, JF ;
PIRSCH, JD ;
RAMOS, EL ;
SALOMON, DR ;
STABLEIN, DM ;
VANBUREN, DH ;
WEST, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (06) :358-363
[2]  
COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
[3]   EVALUATION OF CYCLOSPORIN PHENYTOIN INTERACTION WITH OBSERVATIONS ON CYCLOSPORIN METABOLITES [J].
FREEMAN, DJ ;
LAUPACIS, A ;
KEOWN, PA ;
STILLER, CR ;
CARRUTHERS, SG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (06) :887-893
[4]   High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes [J].
Geisslinger, G ;
Bocker, R ;
Levy, M .
PHARMACEUTICAL RESEARCH, 1996, 13 (08) :1272-1275
[5]   BIOAVAILABILITY OF CYCLOSPORINE WITH CONCOMITANT RIFAMPIN ADMINISTRATION IS MARKEDLY LESS THAN PREDICTED BY HEPATIC ENZYME-INDUCTION [J].
HEBERT, MF ;
ROBERTS, JP ;
PRUEKSARITANONT, T ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :453-457
[6]   IDENTIFICATION OF RIFAMPIN-INDUCIBLE P450IIIA4 (CYP3A4) IN HUMAN SMALL-BOWEL ENTEROCYTES [J].
KOLARS, JC ;
SCHMIEDLINREN, P ;
SCHUETZ, JD ;
FANG, C ;
WATKINS, PB .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) :1871-1878
[7]   CLINICAL PHARMACOKINETICS OF DIPYRONE AND ITS METABOLITES [J].
LEVY, M ;
ZYLBERKATZ, E ;
ROSENKRANZ, B .
CLINICAL PHARMACOKINETICS, 1995, 28 (03) :216-234
[8]  
PONTICELLI C, 1994, TRANSPLANT P, V26, P2490
[9]   RENAL-TRANSPLANTATION WITHOUT STEROIDS [J].
SALAMAN, JR .
PEDIATRIC NEPHROLOGY, 1991, 5 (01) :105-107
[10]   Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism [J].
Thummel, KE ;
OShea, D ;
Paine, MF ;
Shen, DD ;
Kunze, KL ;
Perkins, JD ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (05) :491-502